Comparing Belatacept and Anticalcineurins on Blood Vessel Health in Kidney Transplant Patients

What this Trial Is About

Kidney transplantation is the standard treatment for patients with end-stage renal failure, but common immunosuppressants called anticalcineurin inhibitors can cause cardiovascular problems, which are a major cause of early death in these patients. These drugs affect blood vessel function by reducing nitric oxide production, leading to high blood pressure and chronic kidney graft damage. Belatacept is a newer immunosuppressant that may offer similar rejection protection with better heart and blood vessel safety, but its effect on blood vessel function in humans has not been fully studied. This research compares patients taking Belatacept to those continuing on anticalcineurin inhibitors to see if Belatacept improves blood vessel function, measured by how well arteries dilate. The study includes two groups one switching to Belatacept and one remaining on anticalcineurins, with kidney transplant patients at least one year post-transplant. The goal is to assess whether Belatacept can help prevent vascular damage earlier in treatment. Participants will be monitored over six months to measure how their blood vessels respond, focusing on endothelium-dependent dilation in arteries. Researchers will track kidney function stability, cardiovascular risks, and overall health during this time. The study provides all treatments and visits to observe the effects, with assessments including blood tests and clinical exams to evaluate safety and vascular health.

Comparison of the Effects of Belatacept and Anticalcineurins on Endothelial Function in Renal Transplant Patients - <BELAFENDO>